Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Tongjian, Cui"'
Autor:
Zhihao Lu, Li Kong, Buhai Wang, Junye Wang, Lianke Liu, Yongqian Shu, Lei Yang, Guogui Sun, Guochun Cao, Yinghua Ji, Tongjian Cui, Hu Liu, Wensheng Qiu, Na Li, Gaofeng Li, Hui Luo, Xinfang Hou, Yanqiao Zhang, Wenbin Yue, Liying Xue, Zheng Liu, Yueyin Pan, Shegan Gao, Xiuwen Wang, Zhanyu Pan, Shuqun Zhang, Gen Lin, Yanru Xie, Kangsheng Gu, Tiejun Ren, Weidong Li, Tao Li, Shoufeng Wang, Wei He, Yun Fan, Jun Liang, Bing Xia, Li Zhao, Shuxuan Wang, Lin Shen
Publikováno v:
EClinicalMedicine, Vol 72, Iss , Pp 102623- (2024)
Summary: Background: In ORIENT-15 study, sintilimab plus chemotherapy demonstrated significant improvement on overall survival (OS) versus placebo plus chemotherapy in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC). Here,
Externí odkaz:
https://doaj.org/article/3439ece3dd7b46968792b2d1c86fbbe8
Autor:
Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Lei Yang, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Yuxian Bai, Wei Li, Yiping Zhang, Guanghai Dai, Dong Ma, Jingdong Zhang, Chunmei Bai, Yunchao Huang, Wangjun Liao, Lin Wu, Xi Chen, Yan Yang, Junye Wang, Shoujian Ji, Hui Zhou, Yan Wang, Zhuo Ma, Yanqi Wang, Bo Peng, Jiya Sun, Christoph Mancao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Patients with advanced esophageal cancer have poor prognosis and limited treatment options. This randomized, phase II trial compares the efficacy and safety of the anti-PD-1 antibody sintilimab versus chemotherapy in Chinese patients with esophageal
Externí odkaz:
https://doaj.org/article/ca3209d28c2d4a36b8c9ded73e1588cf
Publikováno v:
European Journal of Inflammation, Vol 20 (2022)
Objective To assess the clinical efficacy and side effects of EGFR-TKI with or without chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma. Methods A total of 103 IIIB or IV EGFR mutation-positive lung adenocarcinoma
Externí odkaz:
https://doaj.org/article/7a0090e932af4584afd3084a64d0e2e8
Autor:
Min Yan, Peng Yuan, Quchang Ouyang, Ying Cheng, Guohui Han, Dewei Wang, Li Ran, Tao Sun, Da Zhao, Yuju Bai, Shun’e Yang, Xiaojia Wang, Rong Wu, Xiaohua Zeng, Herui Yao, Xuening Ji, Jun Jiang, Xiaohua Hu, Haifeng Lin, Liping Zheng, Zhitu Zhu, Wei Ge, Junlan Yang, Tongjian Cui, Xiaozhi Zhang, Fangyang Lu, Wenhui Li, Hongyan Xu, Mafei Kang, Ping Gong, Liqun Zou, Jiang Liu, Hongliang Zhang, Hao Yu, Binghe Xu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Since lobaplatin (LBP) has been approved to treat metastatic breast cancer in China, this study aimed to evaluate the safety and efficacy of LBP-based chemotherapy in clinical practice. Methods: This trial was a prospective, open-label, m
Externí odkaz:
https://doaj.org/article/f1f71ac36fb74f9f9572cb28f74b008f
Publikováno v:
European Journal of Inflammation, Vol 20 (2022)
Introduction: The effectiveness of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) on tumor has been reported. However, the immune-related adverse events (irAEs) and its clinical management of the immune checkpoint i
Externí odkaz:
https://doaj.org/article/90d8db7c2156449bac1fc7cf528d45e2
Publikováno v:
BioMed Research International. 2022:1-15
Background. Biomarker research in head and neck squamous cell carcinoma (HNSCC) is constantly revealing promising findings. An enhancer of polycomb homolog 1 (EPC1) was found to play a procancer role in nasopharyngeal carcinoma (NPC), but its role in
Autor:
Zhihao Lu, Junye Wang, Yongqian Shu, Li Kong, Buhai Wang, Lei Yang, Guochun Cao, Guogui Sun, Yinghua Ji, Hu Liu, Tongjian Cui, Wensheng Qiu, Aziz Zaanan, Roberto Pazo Cid, Hui Zhou, Xing Sun, Yan Wang, Yuling Chen, Haoyuan Li, Lishi Zhang, Lin Shen
Publikováno v:
Cancer Research. 83:CT075-CT075
Background: The ORIENT-15 study (NCT03748134) evaluated sintilimab (anti-PD-1 antibody) plus chemotherapy (Sin+Chemo) versus placebo plus chemotherapy (Chemo) as first-line (1L) treatment of unresectable locally advanced, recurrent, or metastatic eso
Autor:
Yan Yang, Yanqi Wang, Xi Chen, Hui Zhou, Jiya Sun, Nong Xu, Min Tao, Lei Yang, Tongjian Cui, Xiuwen Wang, Lin Wu, Wei Li, Jingdong Zhang, Dong Ma, Yongqian Shu, Junye Wang, Wangjun Liao, Juxiang Xiao, Zhuo Ma, Chunmei Bai, Christoph Mancao, Yi Li, Yunchao Huang, Jianming Xu, Guanghai Dai, Yiping Zhang, Tao Zhang, Quanli Gao, Yuxian Bai, Q. Fan, Chengxu Cui, Bo Peng, Kangsheng Gu, Yunpeng Liu, Shoujian Ji, Yan Wang
This randomized, open-label, multi-center phase 2 study (ClinicalTrials.gov, number NCT03116152) assessed sintilimab, a PD-1 inhibitor, versus chemo in patients with advanced esophageal squamous cell carcinoma (ESCC) refractory to first-line (1L) che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1c38d25a1c18282f9cc6237125fd647
https://doi.org/10.21203/rs.3.rs-469826/v1
https://doi.org/10.21203/rs.3.rs-469826/v1
Publikováno v:
BioMed Research International
BioMed Research International, Vol 2021 (2021)
BioMed Research International, Vol 2021 (2021)
Objective. We aim to investigate the correlation between FCGR2A mRNA level and prognosis of head and neck squamous cancer (HNSC) in public databases. In addition, we investigated the correlation between FCGR2A expression and clinicopathological chara
Autor:
Zhihao, Lu, Junye, Wang, Yongqian, Shu, Lianke, Liu, Li, Kong, Lei, Yang, Buhai, Wang, Guogui, Sun, Yinghua, Ji, Guochun, Cao, Hu, Liu, Tongjian, Cui, Na, Li, Wensheng, Qiu, Gaofeng, Li, Xinfang, Hou, Hui, Luo, Liying, Xue, Yanqiao, Zhang, Wenbin, Yue, Zheng, Liu, Xiuwen, Wang, Shegan, Gao, Yueyin, Pan, Marie-Pierre, Galais, Aziz, Zaanan, Zhuo, Ma, Haoyu, Li, Yan, Wang, Lin, Shen, Maria Francisca, Vazquez Rivera
Publikováno v:
BMJ. :e068714
ObjectiveTo evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell